Format

Send to

Choose Destination
Bull Cancer. 2017 Jun;104(6):524-537. doi: 10.1016/j.bulcan.2017.01.010. Epub 2017 Mar 9.

[The human and economic burden of cancer in France in 2014, based on the Sniiram national database].

[Article in French]

Author information

1
Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), 26-50, avenue du Professeur-André-Lemierre, 75986 Paris, France. Electronic address: philippe.tuppin@cnamts.fr.
2
Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), 26-50, avenue du Professeur-André-Lemierre, 75986 Paris, France.

Abstract

INTRODUCTION:

The national health insurance information system (Sniiram) can be used to estimate the national medical and economic burden of cancer. This study reports the annual rates, characteristics and expenditure of people reimbursed for cancer.

METHODS:

Among 57 million general health scheme beneficiaries (86% of the French population), people managed for cancer were identified using algorithms based on hospital diagnoses and full refund for long-term cancer. The reimbursed costs (euros) related to the cancer, paid off by the health insurance, were estimated.

RESULTS:

In 2014, 2.491 million people (4.4%) covered by the general health scheme had a cancer managed (men 1.1 million, 5.1%; women 1.3 million, 4.9%). The annual (2012-2014) average growth rate of patients was 0.8%. The spending related to the cancer was 13.5 billion: 5 billion for primary health care (drugs 2.3 billion), 7.5 billion for the hospital (drugs 1.3 billions) and 900 million for sick leave and invalidity pensions. Spending annual average growth rate (2012-2014) was 4% (drugs 2%). The rates of patients and the relative spending were 1.8% and 2.5 billion for the breast cancer (women), 1.5% and 1.0 billion for prostate cancer, 0.9% and 1.5 billion for the colon cancer, and 0.19% and 1.3 billion for lung cancer.

DISCUSSION:

Cancers establish one of the first groups of chronic diseases pathologies in terms of patients and spending. If the numbers of patients remain stables, the spending increases, mainly for medicines.

KEYWORDS:

Assurance maladie; Cancers pris en charge; Costs; Coûts; Désavantage social; France; Health insurance scheme; Managed cancers; Prevalence; Prévalence; Social deprivation

PMID:
28285755
DOI:
10.1016/j.bulcan.2017.01.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center